Noonan Syndrome Clinical Trial
— NoonanOfficial title:
Constitution of a Biological Collection to Study the Pathophysiology in Noonan Syndrome and to Identify Predictive Factors of Disease Progression
The present study will establish a collection of biological samples from Noonan patients to be used for research purposes only, with due respect for confidentiality.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | January 26, 2032 |
Est. primary completion date | January 26, 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 99 Years |
Eligibility | Inclusion Criteria: - Children aged at least 3 years old or adult with Noonan syndrome - Patients affiliated to or beneficiaries of a social security scheme - Patients able to receive information on the progress of the study and understand the information form to participate in the study. That implies to master the French language and not to be subject to a restriction of rights by the judicial authorities - Patients or legal representative who have given their consent to participate in the study (expression of no objection) Exclusion Criteria: - Patients subject to a legal protection measure (guardianship, curators, or safeguard of justice) - Pregnant or breastfeeding women |
Country | Name | City | State |
---|---|---|---|
France | Purpan University Hospital | Toulouse |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Toulouse |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Constitution of a biological collection from patients with Noonan or related syndromes. | extra sample of blood and urine will be collected | inclusion |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01529944 -
Genetic Testing of Noonan Subjects Previously Treated With Norditropin®. An Extension to Trial GHNOO-1658
|
Phase 3 | |
Completed |
NCT00452725 -
Effect of MAXOMAT ® on the Growth of Small Children to NOONAN's Syndrome
|
Phase 3 | |
Recruiting |
NCT05761314 -
Solid Tumors in RASopathies
|
N/A | |
Recruiting |
NCT04463316 -
GROWing Up With Rare GENEtic Syndromes
|
||
Recruiting |
NCT06267807 -
Lymphatic Phenotype in Noonan Syndrome Spectrum Disorders
|
N/A | |
Enrolling by invitation |
NCT05308927 -
French Registry of Children Treated With Norditropin® for Short Stature Associated With Noonan Syndrome
|
||
Recruiting |
NCT04395495 -
RASopathy Biorepository
|
||
Completed |
NCT01529840 -
Somatropin Effect on Linear Growth and Final Height in Subjects With Noonan Syndrome
|
Phase 3 | |
Recruiting |
NCT06355622 -
Prevalence and Characterization of Pain in RASopathies
|
N/A | |
Completed |
NCT02713945 -
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome
|
Phase 3 | |
Recruiting |
NCT05361811 -
Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial
|
N/A | |
Completed |
NCT03435627 -
Post Marketing Surveillance on Long-term Use With Norditropin® (Short Stature Due to Noonan Syndrome)
|
||
Recruiting |
NCT05723835 -
A Research Study Looking at How Safe Somapacitan is and How Well it Works in Children Who Need Help to Grow - REAL 9
|
Phase 3 | |
Completed |
NCT02486731 -
Hormonal Sensitivity in Patients With Noonan and LEOPARD Syndromes
|
||
Completed |
NCT01927861 -
Investigating the Long-term Efficacy and Safety of Two Doses of NN-220 (Somatropin) in Short Stature Due to Noonan Syndrome
|
Phase 3 | |
Recruiting |
NCT04888936 -
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies
|
||
Recruiting |
NCT06331117 -
Effect of RAS/MAPK Pathway Hyperactivation on Growth' and Bone' Profile of the RASopathies
|
N/A | |
Completed |
NCT00960128 -
Observational Prospective Study on Patients Treated With Norditropin®
|
N/A | |
Terminated |
NCT00351221 -
Research Study Using Recombinant Human Insulin-Like Growth Factor-1/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 for Children With Noonan Syndrome
|
Phase 2 |